EGFR and adenocarcinoma: It was observed that KRAS mutations are detected in 8% of patients, mainly those with adenocarcinoma, and are mutually exclusive from EGFR mutations as previously reported37, 38, although one patient harbored KRAS-G12L, EGFR amplification and exon19-deletion simultaneously (Fig. 6a).